Skip to main content

Stock Market Insights

November 8, 2026 in Articles

Sai Life Sciences Growth Story: India’s Emerging CRDMO Powerhouse

Sai Life Sciences growth story highlighting India's CRDMO industry, pharmaceutical research, drug development, manufacturing capabilities and long-term business growth opportunities.

The pharmaceutical industry in India is changing as medicines are becoming more complex, and funding is becoming tighter, so companies are looking for new ways to work with partners. They want to team up with organizations that can help them get their products to market faster. In this new landscape, Sai Life Sciences Growth Story is a great example of how India is becoming a major player in the field of contract research, development and manufacturing. The company started small in Hyderabad, India in 1999, but over the years, it has grown into a world-class operation with facilities in India, the UK, and the US. Today, Sai Life Sciences is a leader in the industry, with a focus on cutting-edge science, operational excellence, and taking care of the environment. It’s a new kind of company that is helping to shape the future of drug discovery and development. With its advanced facilities and worldwide reach, this company is well-positioned to help companies get their products to market quickly. Their success is a testament to India’s growing capabilities in the pharmaceutical industry.

Sai added skills, abilities to deal with the drug discovery process

Sai Life Sciences growth story started back in 1999 as Sai Dru Syn Laboratories, offering basic medicinal chemistry services to biotech companies in the US. Over the next 25 years, the company grew slowly and carefully, adding new skills and abilities to cover every step of the drug discovery and development process. In 2002, it established specialized labs at the IKP Knowledge Park in Hyderabad. Two years later, in 2004, it acquired facilities in Bollarum and Bidar that met Good Manufacturing Practice (GMP) standards, allowing it to produce high-quality products. This was all part of the company’s plan to expand and improve its services. By taking things one step at a time, Sai Life Sciences was able to build a strong foundation and become a key player in the industry. Today, it is a trusted name in the field of drug discovery and development, offering a wide range of services and capabilities to its clients.

Sai attracted investors from around the world

Sai Life Sciences saw a great opportunity in combining contract development and manufacturing, so they attracted major investors from around the world to help them grow. Well-known venture capital and private equity firms like Advantium LLC, Sequoia Capital, and Tata Capital invested in the company. Later, other major players like HBM Healthcare Investments and TPG Capital also joined in-TPG Capital came on board in 2018. This influx of capital helped fund major projects, including “SaiNxt” a substantial transformation plan that started in 2019 with a $150 million investment. The company is using this money to implement significant changes. With the support of these investors, Sai Life Sciences growth story can take its business to the next level.

SaiNxt was the starting point for the company’s significant push into international markets, which resulted in establishing top-notch research centers in Greater Boston, USA, and Manchester, UK. By putting down roots in the world’s most exciting biotech hotspots, the company connected the dots between innovative Western networks and India’s cost-effective, high-volume capabilities. This strategic growth led to Sai Life Sciences being listed on India’s stock exchanges (NSE and BSE) in 2024. The company’s progress hasn’t slowed down, with 2026 seeing the launch of a special veterinary active pharmaceutical ingredient facility in Bidar and the opening of a substantial new R&D campus in Hyderabad. This new campus is a big deal and signifies that the company is still moving forward.

Sai kept its innovation ahead of the curve

The pharmaceutical industry is changing quickly, with a significant focus on complex biological and synthetic treatments. Sai Life Sciences growth story is ahead of the curve, anticipating major trends instead of merely responding to them. One of the main reasons for this change is the enormous demand for treatments that assist with metabolism and weight loss, especially medicines that target the Glucagon-Like Peptide-1 (GLP-1) receptor. The success of these weight loss treatments has greatly increased the market for peptide synthesis, which is a key research area. This shift is driving innovation and growth in the industry, with companies like Sai leading the way.

It has established a specialized research center for peptides at its campus in Hyderabad. This center has a team of over 50 scientists who work with advanced machines and automation to design, make, and modify complex peptides. The company is also utilizing its expertise in peptides to enter the business of making Antibody-Drug Conjugates, a very profitable and technically challenging field. Recently, some very successful medicines like Enhertu, made by Daiichi Sankyo and AstraZeneca, have made this field very popular again. As a result, biotech companies are looking for partners who can handle the complicated process of making these medicines, which involves many different components.

Sai redefined their partnership model

As money gets tight and it’s hard for new biopharmaceutical companies to get funding, the old way of doing things-where they outsourced simple tasks and kept the important scientific work in-house-just isn’t working anymore. Now, these companies are turning to Sai Life Sciences as if they were part of their own team. This company is taking on more responsibilities, including the critical step of target validation, which is when a company checks if a biological process is truly causing a disease. This is significant because it helps them decide whether to move forward with developing a new drug. Companies are now trusting Sai to perform this important work and to help them determine which molecules to pursue.

Sai Life Sciences growth story is very open about what it does, but it also ensures that anything new it discovers belongs only to the client. This helps build a lot of trust and means the company won’t compete with the people it works with, allowing it to remain a reliable partner. Getting engineers involved early on in the development of a new molecule can help avoid significant problems later on. Normally, a molecule might work great in a small-scale lab setting but then fail when made on a much larger scale.

Sai aims 100% renewable energy sources

Sai Life Sciences is making a big push to include environmental, social, and governance principles in its main business plan. Today, pharmaceutical companies face immense pressure from regulators and consumers to reduce their carbon footprint in their global supply chains. As a member of the Pharmaceutical Supply Chain Initiative, Sai Life Sciences understands that caring for the environment is no longer just a nice thing to do-it’s a key factor in its success. By doing so, the company is setting itself apart from others in the industry.

Sai Life Sciences made a big promise to go green, and it just achieved a major goal. Its vast campus in Bidar, which includes a large factory for manufacturing medicine ingredients and a new area for animal health, now runs entirely on renewable energy. This marks a first for any manufacturing site in India’s CRDMO industry-Bidar is the first to use 100 percent renewable electricity.

The company has made significant strides in utilizing renewable energy over the past few years. It started with 21% of its energy coming from renewable sources in 2020, then jumped to 57% in 2022, and 89% in 2024. By 2026, the company aims to source 100% of its energy from renewable sources. To achieve this, the company has invested in solar and wind energy, including a major wind project capable of producing 2.7 MW of power. It has also used special certificates to offset its carbon emissions, which has reduced its emissions by around 35,110 tonnes of CO2 each year. 

Sai gets 105% jump in net profit

Sai is doing exceptionally well financially, with a 16% increase in revenue and an impressive jump of 105% in net profit for the year 2025. This is due to their strong commercial plans and agreements with other companies to manufacture their products. They are also working on new medicines and making progress in areas such as oral peptide delivery systems and next-generation ADC linkers. At the same time, they’re being recognized as a great place to work and are collaborating with the University of Liverpool on various projects. The company is growing and improving at what they do, which is helping them to keep moving forward. Sai Life Sciences growth story is a great example of how India’s pharmaceutical industry is maturing. By combining research and development with large-scale production, they are demonstrating to the world what they can achieve.

Image Credit: Canva

Disclaimer:

Stock market investments are subject to market risks. The information shared on this website is based on publicly available sources and is for educational purposes. Nothing on this website should be considered a recommendation to buy, sell, or hold any stock or mutual fund. You should perform your own research and seek advice from a SEBI-registered financial advisor before making investment decisions, because Past performance is not indicative of future results.




Leave a Reply

Your email address will not be published. Required fields are marked *

By browsing this website, you agree to our privacy policy.
I Agree